Our pipeline consists of innovative investigational therapies designed to address key limitations of existing cancer therapies. We are developing a suite of precision oncology assets, including small molecule, orally available targeted therapies designed to bind to their targets with greater precision and affinity than other kinase inhibitors, and a potentially first-in-class Claudin18.2 antibody-drug conjugate that has the potential to address unmet need in gastrointestinal cancers.
TRIDENT-1: Advanced NSCLC (ROS1) And Solid Tumors (NTRK)
CARE: Pediatric Advanced Solid Tumors
TRIDENT-2: KRAS-Targeting Combination
Elzovantinib (TPX-0022) (MET)1
SHIELD-1: Advanced Solid Tumors
SHIELD-2: EGFR Combination2
SWORD-1: Advanced Solid Tumors
FORGE-1: Advanced NSCLC
TPX-4589 FORMERLY LM-302 (CLAUDIN18.2)4
Advanced solid tumors
p21 Activated Kinase
Multiple GTPase Oncology Targets
1Turning Point retains worldwide rights, except in Greater China (partnered with ZaiLab)
2Clinical collaboration with EQRx.
3Turning Point retains worldwide rights.
4Turning Point licensed worldwide rights from LaNova Medicines (excluding Greater China and South Korea).